Announcements Health & Medicine ShareFacebookTwitterLinkedinTelegramEmailClipboard Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study We are proud to have another publication in WM: “Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study,” (Journal of Clinical Oncology, 21/7/2023)Read More
The session has ended for security reasons.